This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
by Zacks Equity Research
Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
MDGLPositive Net Change LQDANegative Net Change KNSANegative Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut
by Zacks Equity Research
Alnylam stock plunges after Q2 earnings and revenue miss estimates, while a cut to 2026 product sales guidance overshadows record quarterly Amvuttra sales.
ALNYPositive Net Change REGNNegative Net Change NVSNegative Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
by Zacks Equity Research
Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.
IONSPositive Net Change AZNNegative Net Change GSKNegative Net Change BIIBNegative Net Change
biotechs earnings medical pharmaceuticals
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
by Zacks Equity Research
Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.
CORTNegative Net Change NBIXPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechnology biotechs medical
BMY Q2 Earnings Beat Estimates, '26 View Raised, Stock Up
by Zacks Equity Research
Bristol Myers??? tops Q2 earnings and revenue estimates, raises 2026 guidance, and sees strong momentum from its Growth Portfolio and higher Eliquis demand.
BMYPositive Net Change PFEPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
by Zacks Equity Research
Viking Therapeutics beats second-quarter loss estimates as it advances late-stage obesity studies despite sharply higher R&D spending tied to its expanding pipeline.
VKTXPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechs earnings medical
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
by Zacks Equity Research
BHC beats Q2 estimates as Salix, Solta Medical and Bausch + Lomb fuel growth, lifting 2026 revenue and EBITDA guidance after strong earnings.
BHCPositive Net Change AMRNNegative Net Change LQDANegative Net Change HRMYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength
by Zacks Equity Research
REGN's Q2 earnings and revenues beat estimates as robust Eylea HD demand and higher Dupixent profits offset declining Eylea sales.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
by Zacks Equity Research
uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.
QUREPositive Net Change NBIXPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechnology biotechs medical
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
by Zacks Equity Research
AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.
AMRNNegative Net Change NBIXPositive Net Change LQDANegative Net Change HRMYPositive Net Change
biotechs